The effect of osteoporosis on medical and implant-related complications following total shoulder arthroplasty: a propensity-matched cohort analysis

Jad Jack Lawand, Ryan Lopez, Mohammad Daher¹, Peter George Boufadel, Jie Jonathan Yao², Mohamad Fares³, Joseph A Abboud³

¹Brown University, ²Rothman, ³Rothman Orthopaedic Institute INTRODUCTION:

Osteoporosis is a degenerative bone disorder that, with the aging population, is becoming more common in patients seeking total shoulder arthroplasty. While the effects of osteoporosis have been described in the broader orthopedic literature, it is presently unclear how osteoporosis affects total shoulder arthroplasty (TSA) postoperative medical and implant-related outcomes.

METHODS:

A multicenter insurance claims database, TriNetX, was queried for patients between 2011-2021 who underwent TSA with and without osteoporosis. Patients with less than 2-years of follow-up and those with a prior major arthroplasty were excluded. Primary outcomes included 2-year periprosthetic joint infection (PJI), prosthesis dislocation, periprosthetic fracture, and revision surgery. Secondary outcomes included 90-day medical complications and readmissions. Osteoporotic and control patient cohorts were propensity matched in a 1:1 ratio.

RESULTS: 10.363 patients were included after matching in each cohort. Baseline demographic variables were similar between groups, except osteoporotic patients had a lower BMI (28.8 vs 30.8 kg/m2; p < 0.001). Osteoporotic patients undergoing TSA were more likely to experience infection, stroke, pulmonary embolism, deep vein thrombosis, myocardial infarction, anemia, pneumonia, renal failure, transfusion, readmission, and death within 90 days after surgery (p < 0.05. Table 1). At 2 years postoperative, osteoporotic TSA patients experienced an elevated risk of mechanical loosening, PJI, dislocation, periprosthetic fracture, and required revision surgery at a higher rate than control patients (p < 0.05, Table 2). DISCUSSION AND CONCLUSION:

Osteoporotic patients undergoing shoulder arthroplasty are at greater risk for medical complications within the 90-day peri-operative period as well as implant-related complications within 2 years of surgery. Patients and surgeons should be aware of the potential higher risk of complications in osteoporotic patients following SA, and further investigation into benefits of preoperative management and treatment

enemo	OI .			eralive		managemen		
Table 1: 90-Day F	Postoperative Systemic C Osteoporosis n = 10,363		Outcomes in Patients With Control n = 10,363		and With OR	out Osteoporosis. 95% CI	. Р	
	n	%	n	%				
Infection	45	0.43	26	0.25	1.73	(1.069, 2.812)	0.024	
Sepsis	10	0.10	10	0.01	1.00	(0.416, 2.404)	1	
Wound Disruption	43	0.41	27	0.26	1.60	(0.985, 2.583)	0.055	
Stroke	226	2.18	153	1.48	0.66	(1.205, 1.810)	< 0.001	
Pulmonary Embolism	145	1.40	86	0.83	0.99	(1.297, 2.217)	< 0.001	
Deep Vein Thrombosis	167	1.61	93	0.90	1.43	(1.402, 2.334)	< 0.001	
Myocardial Infarction	166	1.60	94	0.91	1.78	(1.379, 2.294)	< 0.001	
Anemia	1,152	11.12	646	6.23	1.88	(1.701, 2.080)	< 0.001	
Pneumonia	326	3.15	129	1.24	1.42	(2.098, 3.165)	< 0.001	
Urinary Tract Infection	10	0.10	10	0.10	1.00	(0.80, 1.52)	0.535	
Renal Failure	339	3.27	252	2.43	1.12	(1.150, 1.601)	< 0.001	
Transfusion	455	4.39	301	2.90	0.97	(1.324, 1.780)	< 0.001	
Readmission	469	4.53	793	7.65	1.75	(1.554, 1.966)	< 0.001	
Death	143	1.38	110	1.06	1.33	(1.016, 1.675)	< 0.001	

treatment of osteoporosis ar Postoperative Implant-Related Outcomes in Patients With and Without						
Osteoporosis n = 10,363		Control n = 10,363		OR	95% CI	P
n	%	n	%			
172	1.66	98	0.95	1.768	(1.377, 2.269)	<0.001
127	1.26	42	0.41	3.049	(2.149, 4.326)	<0.001
202	1.95	97	0.94	2.104	(1.649, 2.685)	<0.001
33	0.32	12	0.12	2.756	(1.422, 5.338)	0.002
135	1.30	86	0.83	1.496	(1.275, 1.590)	< 0.001
	Osteopera Osteop n = 1 n 172 127 202 33	nr Postoperative Implant-Roman	Postoperative Implant-Related Out	Postoperative Implant-Related Outcomes in Proceedings Control	Postoperative Implant-Related Outcomes in Patients With	Postoperative Implant-Related Outcomes in Patients With and Without Osteoporosis Control n = 10,363 OR 95% CI

necessary.